We report a case of fungemia due to fluconazole'resistant Candida nivariensis (MIC, >128 pg/mD. Internal transcribed spacer PCR followed by microchip gel electrophoresis with positive'testing blood culture revealed a unique pattern different from those of other pathogenic yeast.
CASE REPORT
A 7O-yearold woman with rheumatoid arthritis was hospitalized for treatment of nutritional disorder in September 2006. The patient had received total parenteral nutrition for two months before admission. On day 20, the patient had a fever of 37.8"C, which continued for 5 days. Urine and stool cultures yielded C. albicans, while catheter-tip and blood cultures were negative. Although no source of infection was clinically apparent, she was treated with however, the culture and intravenous fluconazole (400 mg dailt for 27 days. On day 77, patient developed a high fever of 40"C. Blood was drawn for the central venous catheter was removed. Hematological investigations revealed a hemoglobin level of 11.6 g/dl, platelet count of 139x10sniter, and a white cell count of 6.6x10s/liter. C'reactive protein was 6 mg/Iiter, and (1-3)'B-D-glucan level was 153.7 pgAiter. Serum Candida antigen was positive with the Unimedi Candida monotest (Unitica Ltd., Tokyo, Japad. The Bact/Alert blood culture system (Organon Teknika Qo"p., Durham, NC) signaled microbi.t gxo*th on the day after blood collection. As
Gram staining of the blood culture showed yeast, intravenous fluconazole (aOO mg daily) was commenced as empirical therapy. Catheter-tip culture also grew yeast in pure culture. Despite fluconazole administration, the patient remained febrile, and blood culture performed during fluconazole treatment was again positive for yeast. Therefore, the treatment was changed to intravenous voriconazole (aOO mg daily) and micafungin (t5O mg daily) for 7 days based on the results of broth microdilution susceptibility testing performed using a commercial kit (0). ttre MICs of the isolate were as follows: 0.5 pg/ml for amphotericin-B, 2.0 pg/ml for 5-fluorocytosine, 2 pg/ml for miconazole, >16 pg/ml for itraconazole, >128 pg/ml for fluconazole, 4 pg/ml for voriconazohe, and 0.06 pg/ml for micafungrn. The fever resolved 4 days later, and the patient was given MCFG for a further 10 days. There was no evidence of relapse during the next month, when she was transferred to another hospital. (Fig,.1) . Furthermore, C. nivariensr^s is a recently described pathogenic yeast closely related to C. glabrata, and only four cases of C. nivariensis infection have been reportedi three from Spain (1) and one from Ind.onesia (GenBank accession no. EF05 6322). C. nivariensis isolates have been misidentified as C. glabrata using commercial identification kits (1). The same misidentification was made with the strains isolated from the patient in the present stud.y.
CHROMagar Candida medium seems to be useful to d.ifferentiate C. glabrata and C-niuariensis.-However, a PCR'based technique is needed for rapid and specific identification of C. nivariensis (1, 2) .It is well known that C. glabrata and C. krusei are resistant or intermediately susceptible to fluconazole (b), but no susceptibility testing for C. niuariensis has been reported.. Although the blood isolate was resistant to fluconazole, further studies are need.ed. to determine whether strains belonging to C. nivariensis species are resist4nt to azole antifungal agents.
In conclusion, if the patient had been treated. previously with an azole, the possibility of. C. nivariensis infection must be considered as shown in the present study. ITS PCR pattern analysis can not only reliably identlty C.
nivariensis, but is also straightforward and can be completed within 1.b h from positive'testing blood culture bottles.
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